A Phase 1/2 interventional study of Obinutuzumab in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-11.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma by Hoffmann-La Roche — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma · Hoffmann-La Roche.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2007, is one of 4 in phase 1/2, and was the 3rd registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 17 studies in Lymphoma by Hoffmann-La Roche is open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 96 across the 15 interventional studies, 421 across the 2 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
2 of the studies in Lymphoma by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
| NCT06624085Hoffmann-La RocheA Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 2027-03-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy in participants with CD20+ (tumor-infiltrating lymphocytic) Malignant Disease, including B-cell chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). The primary objective for the phase II part of the study is to investigate the efficacy and safety of one dose of obinutuzumab in participants with relapsed/refractory CLL and NHL that is, in turn, either indolent (iNHL) or aggressive (aNHL).
It is an open label dose escalating study in phase I and open label in phase II, but the two doses in iNHL \& aNHL are randomized (to high or low dose of the same open label treatment). CLL was not randomized as only one dose level was used.
Participants with a response who might gain additional benefit from being treated again in the opinion of the investigator may be enrolled in a Retreatment Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
Drug: Obinutuzumab
Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
Drug: Obinutuzumab
Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
Drug: Obinutuzumab
Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
Drug: Obinutuzumab
Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
Drug: Obinutuzumab
Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
Drug: Obinutuzumab
Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
Drug: Obinutuzumab
Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
Drug: Obinutuzumab
Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
Also known as: RO5072759, GA101
Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study
Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.
Time frame: Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)
Percentage of Participants With Best Overall Response in Phase II of the Study
Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)
Time frame: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study
A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.
Time frame: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
Percentage of Participants With Partial Response (PR) in Phase II of the Study
A PR was defined as a \>=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by \>=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.
Time frame: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
Progression-free Survival (PFS) in Phase II of the Study
PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.
Time frame: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
Duration of Response by Disease Type in Phase II of the Study
Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.
Time frame: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
Participants With Event-Free Survival (EFS) in Phase II of the Study
EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.
Time frame: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study
B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L.
Time frame: by the end of Phase II (within 3 years, 4 months)
Percentage of Retreated Participants With Response
Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.
Time frame: by Cutoff Date: 25 November 2013 (within 4 years, 2 months)
Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants
Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.
Time frame: at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)
Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study
Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.
Time frame: Day 1 of Cycle 1
Maximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients
Time frame: at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)
Different patients were recruited into Phase I and Phase II, and analyzed separately based on their disease. In this adaptive trial design, some of those same patients were included in follow-up even if they did not complete treatment, and 13 who had initially responded to treatment but subsequently progressed were retreated.
| Milestone | 50-2000 mg Phase I, NHL | 400-2000 mg Phase I, CLL | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|---|---|
| Started | 21 | 13 | 18 | 22 | 21 | 19 | 20 |
| Completed treatment | 11 | 13 | 13 | 18 | 9 | 9 | 13 |
| Started follow-up | 20 | 13 | 17 | 21 | 17 | 16 | 19 |
| Completed follow-up | 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| Retreated population | 2 | 2 | 1 | 4 | 2 | 2 | 0 |
| Completed | 2 | 0 | 0 | 1 | 1 | 0 | 1 |
| Not completed | 19 | 13 | 18 | 21 | 20 | 19 | 19 |
Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.
| percentage of participants | 50/100 mg - Phase I, NHL | 100/200 mg - Phase I, NHL | 200/400 mg - Phase I, NHL | 400/800 mg - Phase I, NHL | 800/1200 mg - Phase I, NHL | 1200/2000 mg - Phase I, NHL | 1600/800 mg - Phase I, NHL | 400/800 mg - Phase I, CLL | 800/1200 mg - Phase I, CLL | 1200/2000 mg - Phase I, CLL | 1000/1000 mg - Phase I, CLL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)
| percentage of participants | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|
| Percentage of Participants With Best Overall Response in Phase II of the Study | 33.3 | 63.6 | 23.8 | 36.8 | 30.0 |
A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.
| percentage of participants | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|
| CR | 5.6 | 13.6 | 9.5 | 15.8 | 5.0 |
| CRu | 5.6 | 9.1 | 4.8 | 0.0 | NA |
| CRi | NA | NA | NA | NA | 0.0 |
A PR was defined as a \>=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by \>=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.
| percentage of participants | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|
| Percentage of Participants With Partial Response (PR) in Phase II of the Study | 22.2 | 40.9 | 9.5 | 21.1 | 25.0 |
PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.
| days | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) in Phase II of the Study | 182 (106 to 526) | 361 (343 to 678) | 78 (42 to 260) | 83 (43 to 339) | 324 (217 to 357) |
Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.
| days | Phase II, iNHL | Phase II, aNHL | Phase II, CLL |
|---|---|---|---|
| Duration of Response by Disease Type in Phase II of the Study | 523 (23 to 952) | 298 (95 to 929) | 272.5 (23 to 794) |
EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.
| participants | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|
| Participants With Event-Free Survival (EFS) in Phase II of the Study | 5 | 6 | 2 | 3 | 4 |
B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L.
| participants | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL |
|---|---|---|---|---|---|
| within 6 months (n=11,19,11,12,13) | 0 | 0 | 0 | 0 | 3 |
| within 9 months (n=8,17,6,5,10) | 0 | 0 | 0 | 1 | 0 |
| within 12 months (n=5,16,4,5,9) | 0 | 2 | 1 | 0 | 3 |
| within 18 months (n=4,13,3,3,8) | 0 | 1 | 0 | 1 | 2 |
| within 24 months (n=3,10,2,3,5) | 2 | 2 | 1 | 0 | 2 |
| after 24 months (n=3,4,1,2,0) | 1 | 0 | 0 | 1 | 0 |
Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.
| percentage of participants | Retreated Participants |
|---|---|
| Best overall response | 62 |
| Complete response | 23 |
| Partial response | 38 |
Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.
| µm/ml*day | 400 mg - Phase I, NHL | 800 mg - Phase I, NHL | 1200 mg - Phase I, NHL | 2000 mg - Phase I, NHL |
|---|---|---|---|---|
| Cycle 1 Day 1 (n=4,6,6,0) | 134 ± 27.1 | 234 ± 63.1 | 307 ± 30.6 | NA ± NA |
| Cycle 1 Day 8 (n=0,4,6,6) | NA ± NA | 367 ± 24.2 | 449 ± 26.4 | 714 ± 28.6 |
| Cycle 8 (n=0,5,5,5) | NA ± NA | 698 ± 65.4 | 1070 ± 62.6 | 1380 ± 66.1 |
Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.
| µm/ml*day | 400 mg - Phase I, NHL | 800 mg - Phase I, NHL | 1200 mg - Phase I, NHL | 2000 mg - Phase I, NHL |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study | 459 ± 64.7 | 993 ± 30.5 | 1057 ± 60.5 | 146 ± 49.6 |
| micrograms/mL | 400 mg - Phase I, CLL | 800 mg - Phase I, CLL | 1200 mg - Phase I, CLL | 2000 mg - Phase I, CLL |
|---|---|---|---|---|
| Cycle 1 Day 1 (n=3,3,3,0) | 216 ± 34.1 | 210 ± 74.0 | 307 ± 21.4 | NA ± NA |
| Cycle 1 Day 8 (n=0,0,3,3) | NA ± NA | NA ± NA | 437 ± 11.8 | 735 ± 9.79 |
| Cycle 8 (n=3,3,3,4) | 485 ± 48.1 | 573 ± 73.2 | 741 ± 32.8 | 1730 ± 32.6 |
Collected over Through final cut off in November 2013. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population | — | 46/134 (34.3%) | 123/134 (91.8%) |
| Event | Safety Population |
|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 8/134 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/134 |
| PyrexiaGeneral disorders | 4/134 |
| Tumour lysis sydromeMetabolism and nutrition disorders | 4/134 |
| AnaemiaBlood and lymphatic system disorders | 2/134 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/134 |
| Cardiac failureCardiac disorders | 2/134 |
| Abdominal painGastrointestinal disorders | 2/134 |
| Lung infectionInfections and infestations | 2/134 |
| Aplasia pure red cellBlood and lymphatic system disorders | 1/134 |
| Event | Safety Population |
|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 107/134 |
| AstheniaGeneral disorders | 35/134 |
| DiarrhoeaGastrointestinal disorders | 23/134 |
| LymphopeniaBlood and lymphatic system disorders | 19/134 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/134 |
| AnaemiaBlood and lymphatic system disorders | 18/134 |
| NeutropeniaBlood and lymphatic system disorders | 18/134 |
| ThrombocytopeniaBlood and lymphatic system disorders | 15/134 |
| BronchitisInfections and infestations | 15/134 |
| NasopharyngitisInfections and infestations | 15/134 |
Safety population: All enrolled participants who had received at least 1 dose of obinutuzumab.
| Age, Categorical(Participants) | 50-2000 mg Phase I, NHL | 400-2000 mg Phase I, CLL | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 7 | 14 | 14 | 6 | 7 | 11 | 70 |
| >=65 years | 10 | 6 | 4 | 8 | 15 | 12 | 9 | 64 |
| Sex: Female, Male(Participants) | 50-2000 mg Phase I, NHL | 400-2000 mg Phase I, CLL | 400/400 mg - Phase II, iNHL | 1600/800 mg - Phase II, iNHL | 400/400 mg - Phase II, aNHL | 1600/800 mg - Phase II, aNHL | 1000/1000 mg - Phase II, CLL | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 12 | 4 | 6 | 9 | 8 | 5 | 8 | 52 |
| Male | 9 | 9 | 12 | 13 | 13 | 14 | 12 | 82 |
The record gives a start of Sep 2007, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab